29
https://pubmed.ncbi.nlm.nih.gov/38092996
The study found that pre-exposure prophylaxis with tixagevimab/cilgavimab (Evusheld) was effective in preventing severe COVID-19 in adult patients with hematology malignancies, even in those with complete vaccination status or positive seroconversion.
